Joanne Jenkins Lager - Mar 11, 2022 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Medical Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Mar 11, 2022
Transactions value $
-$110,985
Form type
4
Date filed
3/14/2022, 08:01 PM
Previous filing
Feb 14, 2022
Next filing
Mar 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Options Exercise $15.1K +3.5K $4.30 3.5K Mar 11, 2022 Direct
transaction ITOS Common Stock Sale -$126K -3.5K -100% $36.01 0 Mar 11, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Award $0 +85K $0.00 85K Mar 11, 2022 Common Stock 85K $36.21 Direct F1
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -3.5K -1.92% $0.00 179K Mar 11, 2022 Common Stock 3.5K $4.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option shall vest over 4 years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer.
F2 One-fourth of the shares subject to the stock option vested on April 1, 2020. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date